SEARCH

SEARCH BY CITATION

All AASLD Practice Guidelines are updated annually. If you are viewing a Practice Guideline that is more than 12 months old, please visit www.aasld.org for an update in the material.

Preamble

  1. Top of page
  2. Preamble
  3. Introduction
  4. Advances in Management of Ascites
  5. Bacterial Infections
  6. Hepatorenal Syndrome
  7. References

Ascites is the most common of the three major complications of cirrhosis, the other complications being hepatic encephalopathy and variceal hemorrhage.1 Cirrhosis is the most common cause of ascites in the United States.2 Development of ascites may be the first evidence of the presence of cirrhosis. Obesity makes the physical examination less helpful in detecting ascites.3 Imaging may provide the first evidence of the presence of ascites. Patients with ascites are frequently admitted to hospitals. Effective care of these patients can reduce the frequency of these readmissions. This version of the American Association for the Study of Liver Diseases Practice Guideline is the fourth iteration of this guideline and represents a thorough update of the 2009 version.

Introduction

  1. Top of page
  2. Preamble
  3. Introduction
  4. Advances in Management of Ascites
  5. Bacterial Infections
  6. Hepatorenal Syndrome
  7. References

In this revision, the treatment options are now divided into first-line, second-line, third-line, and experimental options. There is a new section on drugs to be avoided or used with caution. Blood pressure in patients with cirrhosis and ascites is supported by elevated levels of vasoconstrictors; these vasoconstrictors are compensating for the vasodilatory effect of nitric oxide.4 Arterial pressure independently predicts survival in patients with cirrhosis; those with a mean arterial pressure (MAP) >82 mmHg have a 1-year survival of 70%, compared to 40% for those ≤82 mmHg.5 Drugs that inhibit the effects of these vasoconstrictors would be expected to lower blood pressure; they have been documented to do so.6 Lowering blood pressure might worsen survival.

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers should be avoided or used with caution in patients with cirrhosis and ascites. The European Association for the Study of the Liver practice guideline on ascites recommends that “…they should generally not be used in patients with ascites.”7 This revised guideline reinforces this admonition.

“Cirrhosis cures hypertension.” In the current era, many patients, especially those with obesity and a component of nonalcoholic steatohepatitis (NASH), have hypertension before they decompensate. Normalization of systemic blood pressure is perhaps the only perquisite of cirrhosis. In the situation where angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are used, blood pressure and renal function must be monitored carefully to avoid rapid development of renal failure. Monitoring of blood pressure at home provides useful information for the provider to factor into the decision when to taper or stop antihypertensives.

Propranolol has been shown to shorten survival in patients with refractory ascites in a prospective study.8 This could be the result of its negative effect on blood pressure and the increase in the rate of paracentesis-induced circulatory dysfunction that is noted in patients who are taking propranolol in the setting of refractory ascites.9 Blood pressure and renal function should be monitored closely in patients who have refractory ascites. The risks versus benefits of beta blockers must be weighed carefully in each patient. Consideration should be given to discontinuing beta blockers or not initiating beta blockers in those patients with refractory ascites and those who develop worsening hypotension or worsening azotemia.

In the current version of this guideline, there are also new sections on umbilical hernias, hepatic hydrothorax, and cellulitis. Chest-tube insertion in hepatic hydrothorax is advised against, based on older and newer studies.10, 11 Percutaneous endoscopic gastrostomy is advised against in patients with cirrhosis and ascites.12

Advances in Management of Ascites

  1. Top of page
  2. Preamble
  3. Introduction
  4. Advances in Management of Ascites
  5. Bacterial Infections
  6. Hepatorenal Syndrome
  7. References

Many patients with cirrhosis and ascites in the current era have multiple insults to the liver, including alcohol. Cessation of alcohol intake can dramatically improve their degree of liver failure, despite the continued presence of hepatitis C and/or NASH. Refractory ascites can revert to diuretic sensitive and can even disappear such that diuretics can be tapered and even stopped over time. Baclofen has been shown, in a randomized trial that included only patients with alcoholic liver disease, to reduce alcohol craving and alcohol consumption; it can be given at a dose of 5 mg orally three times daily (TID) for 3 days and then 10 mg TID.13 The dose can be tailored upward, with the patient carrying “a pill in the pocket” and taking an extra pill as needed to reduce alcohol craving.14

An outpatient appointment within 7 days of discharge from the hospital has been shown to correlate with lower readmissions rates of patients with heart failure.15 Rapid return to clinic may also reduce the readmission rates of patients with cirrhosis and ascites by frequent adjustment of doses of diuretics and prevention of dehydration versus tense ascites.

The utility of monitoring urine sodium/potassium ratios is reiterated based on new data.16

Vaptans are discussed in this revision. Earlier studies of vaptans had focused on heart failure and included a relatively small number of patients with cirrhosis. These drugs are very expensive and may cause thirst. The largest randomized trial that specifically included only patients with cirrhosis demonstrated no clinical benefit in long-term management of ascites and provided a signal that mortality could be increased in patients taking drugs in this class.17

Oral midodrine at a dose of 7.5 mg TID has been shown, in a randomized trial in patients with refractory or recurrent ascites, to increase urine volume, urine sodium excretion, MAP, and survival.18 Nurses and care givers may be reluctant to give diuretics to profoundly hypotensive patients. Midodrine can be added to diuretics to increase blood pressure and convert refractory ascites back to diuretic sensitive.

Albumin (ALB) infusion after large-volume paracentesis has been controversial. A meta-analysis of 17 trials involving 1,225 patients has been published, demonstrating a reduction in mortality with an odds ratio of death of 0.64 (95% confidence interval [CI]: 0.41-0.98) in the ALB group.19 ALB infusion (6-8 g per liter of fluid removed) is recommended when more than 5 L of ascitic fluid are removed.

Information on the use of transjugular intrahepatic stent-shunt to treat ascites has also been updated.

Bacterial Infections

  1. Top of page
  2. Preamble
  3. Introduction
  4. Advances in Management of Ascites
  5. Bacterial Infections
  6. Hepatorenal Syndrome
  7. References

Widespread use of quinolones to prevent spontaneous bacterial peritonitis (SBP) in high-risk subgroups of patients, as well as frequent hospitalizations and exposure to broad-spectrum antibiotics, have led to a change in flora of infections in patients with cirrhosis; there are more Gram-positives and extended-spectrum B-lactamase-producing Enterobacteriaceae in recent years.20-22 Risk factors for multiresistant infections include nosocomial origin of infection, long-term norfloxacin prophylaxis, recent infection with multiresistant bacteria, and recent use of B-lactam antibiotics.20

Infections with these resistant organisms are associated with a higher mortality20 and can affect and complicate post-transplant care. We may encounter bacteria for which we have no effective treatment.22 To minimize bacterial resistance, it is prudent to limit prophylactic antibiotics to patients with well-defined criteria for SBP prophylaxis, limit duration of antibiotic treatment of infections, and narrow the spectrum of coverage, once susceptibility testing results are available.

Hepatorenal Syndrome

  1. Top of page
  2. Preamble
  3. Introduction
  4. Advances in Management of Ascites
  5. Bacterial Infections
  6. Hepatorenal Syndrome
  7. References

A new biomarker may assist with the diagnosis of hepatorenal syndrome (HRS) and may make it less of a diagnosis of exclusion.23 Urinary neutrophil gelatinase-associated lipocalin is 20 ng/mL in healthy controls, 20 ng/mL in prerenal azotemia, 50 ng/mL in chronic kidney disease, 105 ng/mL in HRS, and 325 ng/mL in acute kidney injury.23 This test has been shown to be superior to three other urine biomarkers, but is not presently available in the United States.24 A meta-analysis of vasoconstrictor treatment (including terlipressin, octreotide/midodrine, and norepinephrine) of type I and II HRS reports that vasoconstrictor drugs with or without ALB reduced mortality, compared with no intervention or ALB alone (relative risk [RR]: 0.82; 95% CI: 0.70-0.96).25 Terlipressin plus ALB reduced mortality, compared to albumin alone (RR, 0.81; 95% CI: 0.68-0.97) with a reduction in mortality in type I, but not type II, HRS.25

Enthusiasm is high for these new treatments.26 There are ongoing randomized, controlled trials that should help place these options in the treatment algorithm. Terlipressin is not yet available in the United States. Until further data are available, ALB, octreotide, and midodrine should be considered in the treatment of type I HRS. ALB and norepinephrine or vasopressin can be considered in the intensive care unit.

Information on the use of transjugular intrahepatic stent-shunt to treat HRS has also been updated.

References

  1. Top of page
  2. Preamble
  3. Introduction
  4. Advances in Management of Ascites
  5. Bacterial Infections
  6. Hepatorenal Syndrome
  7. References
  • 1
    Gines P, Quintero E, Arroyo V, Teres J, Bruguera M, Rimola A, et al. Compensated cirrhosis: natural history and prognostic factors. HEPATOLOGY 1987; 7: 122-128.
  • 2
    Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med 1992; 117: 215-220.
  • 3
    Silk AW, McTeague KM. Reexamining the physical examination for obese patients. JAMA 2011; 305: 193-194.
  • 4
    Sola E, Gines P. Renal and circulatory dysfunction in cirrhosis: current management and future perspectives. J Hepatol 2010; 53: 1135-1145.
  • 5
    Llach J, Gines P, Arroyo V, Rimola A, Tito L, Badalamenti S, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988; 94: 482-487.
  • 6
    Pariente EA, Bataille C, Bercoff E, Lebrec D. Acute effects of catopril on systemic hemodynamics and on renal function in cirrhotic patients with ascites. Gastroenterology 1985; 88: 1255-1259.
  • 7
    Gines P, Angeli P, Lenz K, Moller S, Moore K, Moreau R, et al. EASL clinical practice guideline on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome. J Hepatol 2010; 53: 397-417.
  • 8
    Serste T, Melot C, Francoz C, Durand F, Rautou P-E, Valla D, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. HEPATOLOGY 2010; 52: 1017-1022.
  • 9
    Serste T, Francoz C, Durand F, Rautou P-E, Melot C, Valla D, et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J Hepatol 2011; 55: 794-799.
  • 10
    Runyon BA, Greenblatt M, Ming RHC. Hepatic hydrothorax is a relative contraindication to chest tube insertion. Arch Intern Med 1986; 81: 566-567.
  • 11
    Orman ES, Lok ASF. Outcomes of patients with chest tube insertion for hepatic hydrothorax. Hepatol Int 2009; 3: 582-586.
  • 12
    Baltz JG, Argo CK, Al-Osaimi AM, Northup PG. Mortality after percutaneous endoscopic gastrostomy in patients with cirrhosis: a case series. Gastrointest Endosc 2010; 72: 1072-1075.
  • 13
    Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomized, double-blind controlled study. Lancet 2007; 370: 1915-1922.
  • 14
    Heydtmann M, Macdonald B, Lewsey J, Masson N, Cunningham L, Irnazarow AM, et al. The GABA-B agonist baclofen improves alcohol consumption, psychometrics and may have an effect on the hospital admission rates of patients with alcoholic liver disease. HEPATOLOGY 2012; 56: 1091A.
  • 15
    Hernandez AF, Greiner MA, Fonarow GC, Hammill BG, Heidenreich PA, Yancy CW, et al. Relationship between early physician follow-up and 30-day redmission among Medicare beneficiaries hospitalized for heart failure. JAMA 2010; 303: 1716-1722.
  • 16
    El-Bokl MA, Senousy BE, El-Karmouty KZ, Mohammed IE, Mohammed SM, Shabana SS, Shakaby H. Spot urine sodium for assessing dietary sodium restriction in cirrhotic ascites. World J Gastroenterol 2009; 15: 3631-3635
  • 17
    Wong F, Watson H, Gerbes A, Vilstrup H, Badalamenti S, Bernardi M, et al. Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut 2012; 61: 108-116.
  • 18
    Singh V, Dhungana SP, Singh B, Vijayverghia R, Nain CK, Sharma N, et al. Midodrine in patients with cirrhosis and refractory ascites: a randomized pilot study. J Hepatol 2012; 56: 348-354.
  • 19
    Bernardi M, Carceni P, Navickis RJ, Wilkes MM. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. HEPATOLOGY 2012; 55: 1172-1181.
  • 20
    Fernandez J, Acevedo J, Castro M, Garcia O, Rodriguez de Lope C, Roca D, et al. Prevalence and risk factors of infections by resistant bacteria in cirrhosis: a prospective study. HEPATOLOGY 2012; 55: 1551-1561.
  • 21
    Ariza X, Castellote J, Lora-Tamayo J, Girbau A, Salord S, Rota R, et al. Risk factors for resistance to ceftriaxone and its impact on mortality in community, healthcare, and nosocomial spontaneous bacterial peritonitis. J Hepatol 2012; 56: 825-832.
  • 22
    Runyon BA. Changing flora of bacterial infections in patients with cirrhosis. Liver Int 2010; 30: 1245-1246.
  • 23
    Verna EC, Brown RS, Farraud E, Pichardo EM, Forster CS, Sola-Del Valle DA, et al. Urinary neutrophil gelatinase associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis. Dig Dis Sci 2012; 57: 2362-2370.
  • 24
    Fagundes C, Pepin M-N, Guevara M, Barreto R, Casals G, Sola E, et al. Urinary neutrophil gelatinase-associated lipocalin as a biomarker in the differential diagnosis of impairment of kidney function in cirrhosos. J Hepatol 2012; 57: 267-273.
  • 25
    Gluud LL, Christensen K, Christensen E, Krag A. Systemic review of randomized trials of vasoconstrictor drugs for hepatorenal syndrome. HEPATOLOGY 2010; 51: 576-584.
  • 26
    Sarin SK, Sharma P. Terlipressin: an asset for hepatologists. HEPATOLOGY 2011; 54: 724-728.